Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?

European Journal of Endocrinology

Volumn 156, Issue 5, 2007, Pages 547-554

  Cetani, Filomena ^a   Ambrogini, Elena ^a   Viacava, Paolo ^a   Pardi, Elena ^a   Fanelli, Giovanni ^a   Naccarato, Antonio Giuseppe ^a   Borsari, Simona ^a   Lemmi, Monica ^a   Berti, Piero ^a   Miccoli, Paolo ^a   Pinchera, Aldo ^a   Marcocci, Claudio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; PARAFIBROMIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG METASTASIS; MALE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID TUMOR; PARATHYROIDECTOMY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SKIN METASTASIS; STAINING; VALIDATION PROCESS;

ADENOMA; ADULT; CARCINOMA; CYCLIN D1; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PARATHYROID NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS;

EID: 34249041993     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-06-0720     Document Type: Article

References (27)

1. Marx SJ. Hyperparathyroidim and hypoparathyroid disorders. New England Journal of Medicine 2000 343 1863-1875.
2. Shane E. Clinical review 122: parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2001 2 485-493.
3. De Lellis RA. Parathyroid carcinoma. An overview. Advances in Anatomic Pathology 2005 12 53-61.
4. Bondenson L, Grimelius L, DeLellis RA, Lloyd R, Akerstrom G, Larsson C, Arnold A, Eng C, Shane E & Bilezikian JP. Parathyroid carcinoma. In Pathology and Genetics. Tumours of Endocrine Organs. WHO Classification of Tumours, pp 124-127. Eds. RA DeLellis, RV Lloyd, PU Heitz & C Eng. Lyon: IARC Press, 2004.
5. Grimelius L, DeLellis RA, Bondenson L, Akerstrom G, Larsson C, Arnold A, Pranssila KO, Hendy GN, Depuy D & Eng C. Parathyroid adenoma. In Pathology and Genetics. Tumours of Endocrine Organs. WHO Classification of Tumours, pp 128-132. Eds. RA DeLellis, RV Lloyd, PU Heitz & C Eng, Lyon: IARC Press, 2004.
6. Shantz A & Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973 31 600-605.
7. Cryns VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery AL Jr, Benedict WF & Arnold A. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. New England Journal of Medicine 1994 330 757-761.
8. Dotzenrath C, Teh T, Farnebo F, Cupisti K, Svensson A, Toell A, Goretzki P & Larsson C. Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? Journal of Clinical Endocrinology and Metabolism 1996 8 3194-3196.
9. Cetani F, Pardi E, Viacava P, Dipollina G, Fanelli G, Picone A, Borsari S, Gazzerro E, Miccoli P. Berti P, Pinchera A & Marcocci C. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clinical Endocrinology 2004 60 99-106.
10. Shattuck TM, Kim TS, Costa J, Yandell DW, Imanishi Y, Palanisamy N, Gaz RD, Shoback D, Clark OH, Monchik JM, Wierman ME, Hollenberg A, Tojo K, Chaganti RS & Arnold A. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clinical Endocrinology 2003 59 180-189.
11. Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C & Arnold A. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. New England Journal of Medicine 2003 349 1722-1729.
12. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H & The BT. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. Journal of Medical Genetics 2003 40 657-663.
13. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, Ambrogini E, Gazzerro E, Colussi G, Berti P, Miccoli P, Pinchera A & Marcocci C. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. Journal of Clinical Endocrinology and Metabolism 2004 89 5583-5591.
14. Rubin MR & Silverberg SJ. Editorial: HRPT2 in parathyroid cancer: a piece of the puzzle. Journal of Clinical Endocrinology and Metabolism 2005 90 5505-5507.
15. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Hoog A, Heath H III, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, The BT, Larsson C & Hobbs MR. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumors syndrome. Nature Genetics 2002 32 676-680.
16. Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ & Simonds WF. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 2004 24 1272-1276.
17. Yart A, Gstaiger M, Wirbelauer C, Pecnik M, Anastasiou D, Hess D & Krek W. The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Molecular and Cellular Biology 2005 25 5052-5060.
18. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, Resau JH & Meyerson M. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Molecular and Cellular Biology 2005 25 612-620.
19. Hahn MH & Marsh DJ. Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene 2005 24 6241-6248.
20. Zhao J, Yart A, Frigerio S, Perren A, Schraml P, Weisstanner C, Stallmach T, Krek W & Moch H. Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. Oncogene (Nov 27; Epub ahead of print).
21. Bradley KJ, Bowl MR, Williams SE, Ahmad BN, Partridge CJ, Patmanidi AL, Kennedy AM, Loh NY & Thakker RV. Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 2007 26 1213-1221.
22. Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR, Soo KC, Cheah WK, Cao B, Resau J, Morreau H & Teh BT. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clinical Cancer Research 2004 10 6629-6637.
23. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM & Marsh DJ. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. American Journal of Surgical Pathology 2006 30 1140-1149.
24. Favia G, Lumachi F, Polistina F & D'Amico DF. Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World Journal of Surgery 1998 22 1225-1230.
25. Juhlin C, Larsson C, Yakoleva T, Leibiger I, Leibiger B, Alimov A, Weber G, Hoog A & Villablanca A. Loss of parafibromin expression in a subset of parathyroid adenomas. Endocrine-Related Cancer 2006 13 509-523.
26. Krebs LJ, Shattuck TM & Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 2005 90 5015-5017.
27. Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C, Besser GM, Conceicao, Pereira M, Davie MW, Dudley N, Leite V, Sadler GP, Seller A & Thakker RV. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clinical Endocrinology 2006 64 299-306.